Daren Fearon
About Daren Fearon
Daren Fearon is a Senior Beamline Scientist at Diamond Light Source, specializing in Fragment-Based Drug Discovery and Structure-Based Drug Design. He has extensive experience in protein crystallography, biophysics, and medicinal chemistry, with a background that includes roles at Pfizer, Evotec, and the Institute of Cancer Research.
Work at Diamond Light Source
Daren Fearon currently serves as a Senior Beamline Scientist (XChem) at Diamond Light Source, located at the Harwell Campus in England. He has held this position since 2021. In addition to his role as Senior Beamline Scientist, he has been working at Diamond Light Source as a Beamline Scientist since 2020. His work focuses on advanced techniques in X-ray crystallography, contributing to the field of structural biology and drug discovery.
Education and Expertise
Daren Fearon holds an MSci in Chemistry with Medicinal Chemistry from The University of Glasgow, where he studied from 2003 to 2008. He further pursued a PhD in Medicinal Chemistry and Structural Biology at The Institute of Cancer Research, University of London, completing it from 2008 to 2012. His expertise encompasses Fragment-Based Drug Discovery, Structure-Based Drug Design, protein crystallography, biophysics, and medicinal chemistry.
Background
Daren Fearon's professional background includes a range of roles in both academic and industrial settings. He worked as a Post-Doctoral Research Assistant at the University of Southampton from 2012 to 2014. Prior to that, he served as an Industrial Trainee in Material Sciences at Pfizer from 2006 to 2007 and completed a PhD at the Institute of Cancer Research from 2008 to 2012. He also gained experience as a Senior Scientist I in Structural Biology at Evotec from 2014 to 2020.
Achievements
Throughout his career, Daren Fearon has contributed to significant advancements in the fields of drug discovery and structural biology. His work in Fragment-Based Drug Discovery and Structure-Based Drug Design has been instrumental in the development of new therapeutic strategies. His extensive experience in protein crystallography and biophysics supports his contributions to the scientific community.